Parth Shah
Dartmouth College
Internal medicineOncologyMutation testingLung cancerEpidermal growth factor receptorGuidelineDiagnostic technologyDisease courseEgfr mutationClinical significanceMedicine
Publications 1
#1Parth Shah (Dartmouth College)
#2Jacob Sands (Harvard University)H-Index: 6
Last. Nicola NormannoH-Index: 74
view all 3 authors...
Epidermal growth factor receptor (EGFR) mutation testing in advanced non-small-cell lung cancer (NSCLC) has evolved rapidly over the past decade, largely triggered by the introduction of the targeted EGFR tyrosine kinase inhibitors (TKIs). Initially used to detect common EGFR mutations and determine the most appropriate first-line therapy at diagnosis, testing methodologies have expanded to test for multiple mutations at multiple time points throughout the disease course. Here we review the curr...